Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
Status:
Completed
Trial end date:
2018-07-30
Target enrollment:
Participant gender:
Summary
Bile acids regulating farnesoid X receptor (FXR) interact with hepatitis B virus replication.
EYP001a is a selective, synthetic FXR agonist under development for the treatment of
hepatitis B.
This Phase 1b study is designed primarily to determine the safety, tolerability,
pharmacokinetics and pharmacodynamics of EYP001a in chronically HBV infected subjects.